Credit: Journal of the American College of Cardiology (2024). DOI: 10.1016/j.jacc.2024.02.020 A randomized, placebo-controlled clinical trial led by a collaboration between Duke-NUS Medical School, National Heart Center Singapore (NHCS) and Klinikum Nürnberg, Germany, has revealed surprising new insights into how SGLT2 inhibitor drugs, originally developed for diabetes, benefit patients with heart failure. Contrary to common assumptions, these drugs may improve cardiac outcomes and heart health without acting as diuretics. Heart failure is a condition where the heart cannot pump enough blood to meet the body’s demands, often leading to fluid Read More
No comments:
Post a Comment